Institution · Integrated Nonclinical Development Solutions (United States)

Most cited papers from Integrated Nonclinical Development Solutions (United States)

Integrated Nonclinical Development Solutions (United States)

What are the most cited papers from Integrated Nonclinical Development Solutions (United States)?

The most cited paper from Integrated Nonclinical Development Solutions (United States) is "Structure-guided inhibitor design for human FAAH by interspecies active site conversion" (Mauro Mileni, Douglas S. Johnson, Zhigang Wang et al., 2008), with 153 citations. Next come "Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics" (83) and "Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders" (75).

Published TypeFieldAccess

Showing 30 of 30 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Structure-guided inhibitor design for human FAAH by interspecies active site conversion Mauro Mileni, Douglas S. Johnson, Zhigang Wang et al. · Proceedings of the National Academy of Sciences Open access	27 Aug 2008	153
2	Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics Daniela Bumbaca Yadav, Vikas Kumar Sharma, C. Andrew Boswell et al. · Journal of Biological Chemistry Open access	22 Oct 2015	83
3	Design and Synthesis of Selective Phosphodiesterase 4D (PDE4D) Allosteric Inhibitors for the Treatment of Fragile X Syndrome and Other Brain Disorders Mark E. Gurney, Richard A. Nugent, Xuesheng Mo et al. · Journal of Medicinal Chemistry Open access	23 Apr 2019	75
4	Evaluating Methods for Classifying Expression Data Michael Z. Man, Greg Dyson, Kjell Johnson et al. · Journal of Biopharmaceutical Statistics	15 Dec 2004	54
5	Best Practices for the Development, Scale-up, and Post-approval Change Control of IR and MR Dosage Forms in the Current Quality-by-Design Paradigm Glenn A. Van Buskirk et al. · AAPS PharmSciTech Open access	27 Feb 2014	44
6	High-throughput magnetic resonance imaging in mice for phenotyping and therapeutic evaluation Patrick McConville, Jonathan B. Moody, Bradford Armstrong Moffat · Current Opinion in Chemical Biology Review	6 Jul 2005	33
7	Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats Jessica J. O’Konek, Paul E. Makidon, Jeffrey J. Landers et al. · Human Vaccines & Immunotherapeutics Open access	26 Aug 2015	29
8	Influence of surgically implantable telemetry solutions on in-life and post-mortem toxicology endpoints Theodore J. Baird, Marc B. Bailie, Daniel J. Patrick et al. · Journal of Pharmacological and Toxicological Methods	21 Feb 2013	22
9	Hemangiosarcoma in Mice Administered Pregabalin: Analysis of Genotoxicity, Tumor Incidence, and Tumor Genetics David G. Pegg, Michael R. Bleavins, James P. Herman et al. · Toxicological Sciences Open access	26 Apr 2012	19
10	Pregabalin Induces Hepatic Hypoxia and Increases EndothelialCell Proliferation in Mice, a Process Inhibited by DietaryVitamin E Supplementation Kay A. Criswell, Jon C. Cook, Dennis C. Morse et al. · Toxicological Sciences Open access	26 Apr 2012	16
11	Data Standardization, Pharmaceutical Drug Development, and the 3Rs Laura S. Kaufman, Katrina Gore, Joyce Zandee · ILAR Journal Open access	Dec 2016	14
12	Mode of Action Associated With Development of Hemangiosarcoma in Mice Given Pregabalin and Assessment of Human Relevance Kay A. Criswell, Jon C. Cook, Zbigniew W. Wojcinski et al. · Toxicological Sciences	26 Apr 2012	14
13	Key Components of the Mode of Action for Hemangiosarcoma Induction in Pregabalin-Treated Mice: Evidence of Increased Bicarbonate, Dysregulated Erythropoiesis, Macrophage Activation, and Increased Angiogenic Growth Factors in Mice but Not in Rats Kay A. Criswell, Zbigniew W. Wojcinski, David G. Pegg et al. · Toxicological Sciences	26 Apr 2012	14
14	Improving corrected QT; Why individual correction is not enough Nicholas D. Ether, Sanket R. Jantre, Dhruv B Sharma et al. · Journal of Pharmacological and Toxicological Methods Open access	14 Oct 2021	11
15	Absence of effect of steady state bempedoic acid on cardiac repolarization: Results of a thorough QT/QTc study in healthy volunteers Benny M. Amore, Clay T. Cramer, Diane Elaine MacDougall et al. · Clinical and Translational Science Open access	31 Aug 2021	10
16	Complexities of Clinical Assay Development and Optimization Prior to First-in-Man Immunization Trials – A Description of Immunogenicity Assay Development for the Testing of Samples from a Phase 1 Alzheimer's Vaccine Trial Olivia Hammond, James A. Reynolds, Leonard J. Rubinstein et al. · Journal of Immunoassay and Immunochemistry	12 Sep 2008	10
17	Preclinical Models of Tumor Growth and Response Patrick McConville, William Leland Elliott, Alicia R. Kreger et al. · Humana Press eBooks Book chapter	2007	9
18	Graphical display of histopathology data from toxicology studies for drug discovery and development: An industry perspective Alan P Brown, Philip J Drew, Brian L. Knight et al. · Regulatory Toxicology and Pharmacology	19 Oct 2016	6
19	Interconnectivity of Disparate Nonclinical Data Silos for Drug Discovery and Development Jyotsna Kasturi, Alan P Brown, Paul C. Brown et al. · Therapeutic Innovation & Regulatory Science	25 Apr 2014	3
20	The Intersection of Theatre and Cognitive Neuroscience Flage, Mary Katherine · NEXUS The Liberty Journal of Interdisciplinary Studies	2023	1
21	Back-Flow Ratio of Liquid between Stages in Multi-Stage Bubble Columns Akio Nishiwaki, Tokihiro Kago, Yasuo Kato et al. · KAGAKU KOGAKU RONBUNSHU Open access	1975	1
22	Influence function analysis applied to partial least squares Kjell Johnson, William S. Rayens · Computational Statistics	23 Feb 2007	1
23	Effect of microsphere emboli on the ventilation-perfusion relationship in the rabbit - a pilot study Line Olrik Berthelsen, Annemarie Thuri Kristensen, Göran Hedenstierna et al. · Research at the University of Copenhagen (University of Copenhagen)	2007	0
24	Characterization of a Long-Acting Anti-Human MASP-2 Antibody for the Treatment of Complement-Related Diseases Han X, Yang C, Wang Z et al. · DOAJ (DOAJ: Directory of Open Access Journals) Open access	Nov 2025	0
25	Politisches Denken und die Alternativen einer politischen Reform in Ungarn / Political Thinking in Hungary and the Alternatives of a Political Reform Csaba Gombär · Comparative Southeast European Studies Open access	Oct 1987	0
26	Production of Active Carbon in Cocurrent Multistage Fluidized Beds Junichi Kawabata, Yoneshiro Tazaki, Senji Honma et al. · KAGAKU KOGAKU RONBUNSHU Open access	1978	0
27	A Hidden Link between Subclinical Hypothyroidism and Depression: A literature Review Sabitha Challa, Ahmed S Kabeil, Bithiah Inyang et al. Open access	23 Nov 2021	0
28	Which QT Correction Method is Most Consistent? Nicholas D. Ether, Marc B. Bailie, Derek J. Leishman et al. · The FASEB Journal	May 2021	0
29	Community Opinions on the Collection and Use of Historical Control Data in Nonclinical Toxicity Studies Lauren Murphree Mihalcik, Megan Bausman, Paul C. Brown et al. · Therapeutic Innovation & Regulatory Science	29 Aug 2015	0
30	7 PRECLINICAL CHARACTERIZATION OF PRO 206, AN ORALLY ACTIVE SMALL-MOLECULE HEPATITIS C (HCV) ENTRY INHIBITOR D Qian, Glen A. Coburn, Amy Q. Han et al. · Journal of Hepatology Open access	Apr 2009	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.